All News

RheumNow Podcast square

Future Big BiTEs (6.28.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article
GCA,woman

JAK Inhibitors in Giant Cell Arteritis

Jack Cush, MD

Trials are underway evaluating the potential benefits of JAK inhibitors (JAKi) in giant cell arteritis (GCA) patients who are refractory to standards of care.

Read Article
JAK Janus

New indications for JAK inhibitors

Janet Pope, MD, MPH, FRCPC

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
EULAR24,Roundup

EULAR 2024 Rheumatology Roundup (6.21.2024)

Jack Cush, MD

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article
Convention1.jpg

EULAR 2024 – Day 4 Report

Jack Cush, MD

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.

Read Article
LBP_0.jpg

Achieving drug-free remission in axSpA

EurekAlert!

A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients.

Read Article
GCA,woman

Choices in GCA

David Liew, FRACP

There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.

Read Article
RT @yuz6yusof #EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) #EULARBEST

Dr. John Cush RheumNow ( View Tweet)

New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13

Links:

Dr. John Cush RheumNow ( View Tweet)
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (& good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020

Dr. John Cush RheumNow ( View Tweet)

Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG

Links:

Dr. John Cush RheumNow ( View Tweet)
Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. https://t.co/vN2VZYGqbE https://t.co/MQ3QCJU4SW

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. https://t.co/G96x5UMZOX https://t.co/4cOuIbcHVt

Links:

Dr. John Cush RheumNow ( View Tweet)
Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. https://t.co/HKapiAIHSs https://t.co/QrO4pVNOTo

Links:

Dr. John Cush RheumNow ( View Tweet)
Impact of regulatory warning on JAK inhibitors JAK inhibitors show promise for treating inflammatory rheumatic diseases, but ORAL surveillance 2022 found increased risk of MACE, cancer, and death. https://t.co/BEYgUg1DF4 https://t.co/tsjOZ6emDg

Links:

Dr. John Cush RheumNow ( View Tweet)
RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i? IL17i? JAKi? @eular_org # LBA0001 @Janetbirdope https://t.co/DGOltriVYF
Dr. John Cush RheumNow ( View Tweet)
Summary of #EULAR2024 #ClinicalPearls JAKi have expanding disease data ✅ #GCA w #UPA ✅ Awaiting data in #SLE w #UPA & #Deucravacitinib ✅Use in #JIA ✅No new safety signals @rheumnow @eular_org

Janet Pope Janetbirdope ( View Tweet)

#EULARBEST RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i IL17i JAKi @eular_org @RheumNow LBA0001 https://t.co/gy0TEiHxjo

Links:

Janet Pope Janetbirdope ( View Tweet)

EULAR OP0092 (2024) INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Links:

Peter Nash drpnash ( View Tweet)

EULAR Abstract Archive POS0894 (2024) SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Links:

Peter Nash drpnash ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×